Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sumi Banno"'
Autor:
Hidetsugu Fujigaki, Yasuko Yamamoto, Takenao Koseki, Sumi Banno, Tatsuya Ando, Hiroyasu Ito, Takashi Fujita, Hiroyuki Naruse, Tadayoshi Hata, Saya Moriyama, Yoshimasa Takahashi, Tadaki Suzuki, Takahiro Murakami, Yukihiro Yoshida, Yo Yagura, Takayoshi Oyamada, Masao Takemura, Masashi Kondo, Mitsunaga Iwata, Kuniaki Saito
Publikováno v:
Microbiology Spectrum, Vol 10, Iss 1 (2022)
ABSTRACT To fight severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), mass vaccination has begun in many countries. To investigate the usefulness of a serological assay to predict vaccine ef
Externí odkaz:
https://doaj.org/article/02f37115e02d48b4a436a03cac1f74b1
Autor:
Yoshiharu Ohno, Kota Aoyagi, Kazumasa Arakita, Yohei Doi, Masashi Kondo, Sumi Banno, Kei Kasahara, Taku Ogawa, Hideaki Kato, Ryota Hase, Fumihiro Kashizaki, Koichi Nishi, Tadashi Kamio, Keiko Mitamura, Nobuhiro Ikeda, Atsushi Nakagawa, Yasuko Fujisawa, Akira Taniguchi, Hirotaka Ikeda, Hidekazu Hattori, Kazuhiro Murayama, Hiroshi Toyama
Publikováno v:
Japanese Journal of Radiology. 40:800-813
Purpose Using CT findings from a prospective, randomized, open-label multicenter trial of favipiravir treatment of COVID-19 patients, the purpose of this study was to compare the utility of machine learning (ML)-based algorithm with that of CT-determ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31416724b2fee841ddcbc33bc5a10c9d
https://doi.org/10.1007/s11604-022-01270-5
https://doi.org/10.1007/s11604-022-01270-5
Publikováno v:
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
Favipiravir, an antiviral agent with activity against SARS-CoV-2, was made available to hospitals in Japan for off-label use among COVID-19 patients between 2020 and 2021.A nationwide observational cohort study was conducted on patients who received
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f43dbbf02049bd3c75b02fcff64a5a11
https://pubmed.ncbi.nlm.nih.gov/36307058
https://pubmed.ncbi.nlm.nih.gov/36307058
Autor:
Yoshiharu Ohno, Kota Aoyagi, Kazumasa Arakita, Yohei Doi, Masashi Kondo, Sumi Banno, Kei Kasahara, Taku Ogawa, Hideaki Kato, Ryota Hase, Fumihiro Kashizaki, Koichi Nishi, Tadashi Kamio, Keiko Mitamura, Nobuhiro Ikeda, Atsushi Nakagawa, Yasuko Fujisawa, Akira Taniguchi, Hidetake Ikeda, Hidekazu Hattori, Kazuhiro Murayama, Hiroshi Toyama
Publikováno v:
Japanese journal of radiology. 40(8)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0afa66befa15b80b3af673b498ecafa
https://pubmed.ncbi.nlm.nih.gov/35546372
https://pubmed.ncbi.nlm.nih.gov/35546372
Autor:
Takahiro Murakami, Tatsuya Ando, Tadaki Suzuki, Yukihiro Yoshida, Sumi Banno, Masao Takemura, Hiroyuki Naruse, Yasuko Yamamoto, Masashi Kondo, Mitsunaga Iwata, Hiroyasu Ito, Yo Yagura, Tadayoshi Hata, Takayoshi Oyamada, Yoshimasa Takahashi, Hidetsugu Fujigaki, Takenao Koseki, Kuniaki Saito, Saya Moriyama, Takashi Fujita
BACKGROUNDTo fight severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), mass vaccination has begun in many countries. To investigate the usefulness of a serological assay to predict vaccine e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a010416e0ac9e9104f5baed1205c5e9
https://doi.org/10.1101/2021.07.19.21260728
https://doi.org/10.1101/2021.07.19.21260728
Autor:
Hideki Kasahara, Taku Ogawa, Toshihiko Yokoyama, Hisako Yoshida, Yasuyuki Kato, Takenao Koseki, Daijiro Kabata, Jun-ichi Yoshida, Mayumi Teramachi, Sumi Banno, Masahiro Hirose, Atsushi Nakagawa, Masami Miyata, Michiko Yamamoto, Yohei Doi, Masashi Kondo, Ryota Hase, Masaya Hibino, Masahiro Shinoda, Tomoya Horiguchi, Eri Nakayama, Akifumi Matsuyama, Masaki Terada, Hayato Koba, Hiroki Nakatsumi, Chang Kweng Lim, Hideaki Kato, Yujiro Uchida, Mitsunaga Iwata, Satoshi Taniguchi, Kazuhisa Yokota, Fumihiro Kashizaki, Ayumi Shintani, Takahiro Maeki, Tadashi Kamio, Takumi Imai, Yoshikazu Mutoh, Shigeru Tajima, Nobuhiro Ikeda, Yukio Yuzawa, Toshiyuki Kita, Yoshito Homma, Yu Kasamatsu, Nobuhiro Kodama, Masayuki Saijo
Publikováno v:
Antimicrobial Agents and Chemotherapy
Favipiravir is an oral broad-spectrum inhibitor of viral RNA-dependent RNA polymerase that is approved for treatment of influenza in Japan. We conducted a prospective, randomized, open-label, multicenter trial of favipiravir for the treatment of COVI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bab73346a3f716f48564cfc6eb217026